ID   A549-CEACAM1-4L
AC   CVCL_C0DZ
DR   cancercelllines; CVCL_C0DZ
DR   Wikidata; Q112927064
RX   PubMed=24743304;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:1814; CEACAM1 (Note=Isoform 4L).
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 7
//
RX   PubMed=24743304; DOI=10.1371/journal.pone.0094106; PMCID=PMC3990526;
RA   Singer B.B., Opp L., Heinrich A., Schreiber F., Binding-Liermann R.,
RA   Berrocal-Almanza L.C., Heyl K.A., Muller M.M., Weimann A.,
RA   Zweigner J., Slevogt H.;
RT   "Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered
RT   immune responses.";
RL   PLoS ONE 9:e94106.1-e94106.12(2014).
//